ReviewCurrent issues in molecular biology2026
Glucose Transporters: Structure, Trafficking, Physiology, and Disease Relevance.
Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Glucose transport across biological membranes in mammals depends primarily on two transporter families: the facilitative glucose transporters of the SLC2 family and the sodium-dependent cotransporters of the SLC5 family. Together, these proteins mediate tissue-specific glucose uptake, epithelial absorption and reabsorption, nutrient sensing, and adaptive responses to metabolic stress. This review summarizes current knowledge of transporter classification, structural mechanism, tissue distribution, intracellular trafficking, and disease associations, with emphasis on GLUT1, GLUT2, GLUT3, GLUT4, SGLT1, and SGLT2. It also discusses less well-characterized members of the extended GLUT family, the therapeutic implications of SGLT inhibition, and unresolved questions regarding transporter specificity. Furthermore, the review integrates emerging evidence on CAR-T cell engineering, Alport syndrome, lupus nephritis, erythropoietic responses, and the reduction in dementia risk associated with transporter modulation.
Indexed as
Identifiers
42793217What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.